Chemical subgroup
L01EL – Bruton-Tyrosinkinase (BTK)-Inhibitoren
21Decisions
49Patient groups
Added benefit by patient group
- Considerable4
- Minor7
- Non-quantifiable2
- Not proven36
Decisions, newest first
- 2025-12-18CalquenceAcalabrutinibNot proven
- 2025-12-18CalquenceAcalabrutinibNot proven: 2 of 2 patient groups
- 2025-12-18CalquenceAcalabrutinibNot proven
- 2025-12-18CalquenceAcalabrutinibNot proven
- 2025-10-02JaypircaPirtobrutinibMinor: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2025-08-07JaypircaPirtobrutinibNot proven
- 2024-06-06BrukinsaZanubrutinibNot proven
- 2023-07-20ImbruvicaIbrutinibNot proven: 2 of 2 patient groups
- 2023-06-15BrukinsaZanubrutinibMinor: 1 of 4 patient groupsNot proven: 3 of 4 patient groups
- 2023-06-15BrukinsaZanubrutinibNot proven
- 2023-06-15BrukinsaZanubrutinibMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2022-06-16BrukinsaZanubrutinibNot proven
- 2021-08-05CalquenceAcalabrutinibConsiderable: 1 of 5 patient groupsMinor: 1 of 5 patient groupsNot proven: 3 of 5 patient groups
- 2021-06-03CalquenceAcalabrutinibMinor: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2021-06-03CalquenceAcalabrutinibMinor: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2021-04-01ImbruvicaIbrutinibConsiderable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2020-02-20ImbruvicaIbrutinibMinor: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2020-02-20ImbruvicaIbrutinibNot proven
- 2017-03-16ImbruvicaIbrutinibConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2016-12-15ImbruvicaIbrutinibNot proven: 3 of 3 patient groups
- 2016-07-21ImbruvicaIbrutinibConsiderable: 1 of 6 patient groupsNon-quantifiable: 2 of 6 patient groupsNot proven: 3 of 6 patient groups
Data status: 2026-10-29